AnaCardio
AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure.
€62.5MSeries B
ParticipantPB
Pureos Bioventures
pureosbio.com ↗Activity from announced rounds
Activity in this selectionOct 16, 2026 · Sep 17, 2026
Pureos Bioventures invests in private drug-development companies, with an emphasis on new biological medicines and drug formats.
Venture capital for therapeutic development
Pureos Bioventures backs private companies developing new medicines for serious diseases. Its stated investment focus emphasizes biological drugs and new drug formats. The team combines venture-investment experience with operating, clinical and company-building backgrounds, supporting businesses whose development programs are grounded in scientific research.
Activity recorded by RoundOS
RoundOS records Pureos participation in Tavo Biotherapeutics, NovaGo Therapeutics and AnaCardio. These events span eye disease, central nervous system disorders and heart failure. They show the financings currently covered in this database; the firm’s own website lists a broader portfolio across multiple therapeutic areas.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $71M 1 disclosed · full round size, not this investor’s share